ada standards of care 2025 obesity pharmacotherapy glp-1 agonists and changes in body mass and composition in adults with overweight or with or without type 2 diabetes mellitus: a systematic review and meta-analysis Nutritional priorities to support GLP‐1

Bifidobacterium species, obligate anaerobes colonizing the distal small intestine and colon, support gut homeostasis by metabolizing dietary substrates, inhibiting pathogens, modulating inflammatory responses, maintaining barrier integrity, and contributing to micronutrient and bioactive compound production, with emerging evidence for antitumor potential (23, 24)

Triple peptides for the treatment of obesity Retatrutide, a single peptide linked to a fatty diacid moiety, acts as a triple-agonist targeting three receptors: GIP, GLP-1, and glucagon

Embracing smaller, nutrient-dense portions from day one will help you maximize the weight-loss benefits of the medication while keeping your energy levels stable

Why added sugar impacts GLP-1 Interestingly, research suggests that diets high in added sugars may reduce natural GLP-1 secretion (1)

Each Medicaid enrollee is assigned to a BHO, which helps to coordinate and manage their behavioral health care